V originále
This study aims to analyze the financial impact of the COVID-19 pandemic on the pharmaceutical sector by assessing market volatility, stock performance, and investment behavior across different pandemic waves. It provides a novel perspective by examining the different financial responses of major pharmaceutical companies, Johnson and Johnson, Pfizer, and Moderna, over 949 trading days (March 2019-December 2022). Using statistical tools such as standard deviation and kurtosis, the study identifies volatility patterns and extreme price movements before, during, and after the pandemic. The results show that the first and fourth waves had the highest market volatility, influenced by vaccine development, regulatory decisions and changing investor sentiment. While short-term financial gains were significant, long-term profitability was challenged by market corrections and policy constraints. This study contributes to the literature by providing insights into crisis-driven financial instability and highlights the need for risk aware investment strategies in the pharmaceutical sector.